LU92370I2 - Afatinib, les tautomères, les stéréoisomères et les sels de celui-ci, des sels physiologiquement acceptables de celui-ci avec des acides ou bases organiques ou inorganiques, de préférence un sel maléate de celui-ci, et plus de préférence un sel dimaléate de celui-ci - Google Patents

Afatinib, les tautomères, les stéréoisomères et les sels de celui-ci, des sels physiologiquement acceptables de celui-ci avec des acides ou bases organiques ou inorganiques, de préférence un sel maléate de celui-ci, et plus de préférence un sel dimaléate de celui-ci

Info

Publication number
LU92370I2
LU92370I2 LU92370C LU92370C LU92370I2 LU 92370 I2 LU92370 I2 LU 92370I2 LU 92370 C LU92370 C LU 92370C LU 92370 C LU92370 C LU 92370C LU 92370 I2 LU92370 I2 LU 92370I2
Authority
LU
Luxembourg
Prior art keywords
salts
salt
afatinib
tautomers
stereoisomers
Prior art date
Application number
LU92370C
Other languages
English (en)
French (fr)
Other versions
LU92370I9 (show.php
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92370(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of LU92370I2 publication Critical patent/LU92370I2/fr
Publication of LU92370I9 publication Critical patent/LU92370I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
LU92370C 2000-12-20 2014-01-31 Afatinib, les tautomères, les stéréoisomères et les sels de celui-ci, des sels physiologiquement acceptables de celui-ci avec des acides ou bases organiques ou inorganiques, de préférence un sel maléate de celui-ci, et plus de préférence un sel dimaléate de celui-ci LU92370I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (2)

Publication Number Publication Date
LU92370I2 true LU92370I2 (fr) 2014-03-31
LU92370I9 LU92370I9 (show.php) 2019-01-17

Family

ID=7667887

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92370C LU92370I2 (fr) 2000-12-20 2014-01-31 Afatinib, les tautomères, les stéréoisomères et les sels de celui-ci, des sels physiologiquement acceptables de celui-ci avec des acides ou bases organiques ou inorganiques, de préférence un sel maléate de celui-ci, et plus de préférence un sel dimaléate de celui-ci

Country Status (39)

Country Link
EP (2) EP2112140A1 (show.php)
JP (1) JP3827641B2 (show.php)
KR (1) KR100852102B1 (show.php)
CN (1) CN1277822C (show.php)
AR (1) AR040524A1 (show.php)
AT (1) ATE430136T1 (show.php)
AU (2) AU2002219174B2 (show.php)
BE (1) BE2014C009I2 (show.php)
BG (1) BG66139B1 (show.php)
BR (1) BRPI0116266B8 (show.php)
CA (1) CA2432428C (show.php)
CY (2) CY1109290T1 (show.php)
CZ (1) CZ302721B6 (show.php)
DE (2) DE10063435A1 (show.php)
DK (1) DK1345910T3 (show.php)
EA (1) EA006317B1 (show.php)
EE (1) EE05244B1 (show.php)
ES (1) ES2326617T3 (show.php)
FR (1) FR14C0009I2 (show.php)
HR (1) HRP20030504B1 (show.php)
HU (2) HU228874B1 (show.php)
IL (2) IL156277A0 (show.php)
LT (1) LTC1345910I2 (show.php)
LU (1) LU92370I2 (show.php)
ME (1) ME02777B (show.php)
MX (1) MXPA03005559A (show.php)
MY (1) MY136086A (show.php)
NO (3) NO325672B1 (show.php)
NZ (1) NZ526918A (show.php)
PL (1) PL214798B1 (show.php)
PT (1) PT1345910E (show.php)
RS (1) RS50860B (show.php)
SI (1) SI1345910T1 (show.php)
SK (1) SK287573B6 (show.php)
TW (1) TWI295992B (show.php)
UA (1) UA74614C2 (show.php)
UY (1) UY27078A1 (show.php)
WO (1) WO2002050043A1 (show.php)
ZA (1) ZA200304141B (show.php)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516633A (en) 1999-06-21 2004-09-24 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
SI1667991T1 (sl) 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
KR20080095915A (ko) * 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
CA2833706C (en) * 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
DK1948180T3 (da) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
ES2397181T3 (es) * 2006-01-26 2013-03-05 Boehringer Ingelheim International Gmbh Procedimiento para preparar derivados de quinazolina sustituida con aminocrotonilamino
RU2492864C2 (ru) 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения рака, несущего мутации egfr
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
KR101703941B1 (ko) 2008-11-10 2017-02-07 내셔날 헬스 리서치 인스티튜트 티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
US20120136004A1 (en) * 2009-05-14 2012-05-31 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
US8735409B2 (en) * 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
PT2608792T (pt) 2010-08-26 2018-01-15 Boehringer Ingelheim Int Métodos de administração de um inibidor de egfr
EP2643314B1 (en) 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
EP2753616A1 (en) 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate
CN103073539B (zh) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
TWI532727B (zh) 2012-01-17 2016-05-11 安斯泰來製藥股份有限公司 吡羧醯胺化合物
CN103772380A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US20150368230A1 (en) 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
WO2014180271A1 (zh) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN103254182A (zh) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 一种阿法替尼的制备方法
WO2014183560A1 (zh) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103242303B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN103755688B (zh) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 一种阿法替尼化合物的制备方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EP3089976B1 (en) 2014-01-02 2019-08-14 Teva Pharmaceuticals International GmbH Crystalline forms of afatinib dimaleate
CN105315263B (zh) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 阿法替尼中间体的合成方法
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
RU2720810C2 (ru) * 2015-03-20 2020-05-13 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Соли производного хиназолина и способ их получения
CN105175400B (zh) * 2015-09-29 2018-04-10 河北神威药业有限公司 一种阿法替尼中间体的制备方法
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (zh) * 2016-10-21 2019-05-24 河北神威药业有限公司 一种制备阿法替尼的中间体及其对映异构体的检测方法
BR112019008384A2 (pt) 2016-11-10 2019-07-09 Boehringer Ingelheim Int composição farmacêutica, processos para tratamento e seus usos
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CA3085593A1 (en) * 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
CN110437163A (zh) * 2018-05-03 2019-11-12 斯特恩格林公司 作为酪氨酸激酶抑制剂的嘧啶类化合物
MX2021003517A (es) 2018-09-25 2021-08-16 Black Diamond Therapeutics Inc Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
CN109265449B (zh) * 2018-11-07 2021-11-23 沈阳工业大学 Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109824657A (zh) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 一种二马来酸阿法替尼新晶型及其制备方法和应用
US12435046B2 (en) 2019-08-15 2025-10-07 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN110590682A (zh) * 2019-10-14 2019-12-20 重庆医科大学 一种制备阿法替尼杂质的方法以及制备的杂质
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN114980883A (zh) 2020-01-20 2022-08-30 阿斯利康(瑞典)有限公司 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TWI847289B (zh) * 2021-09-30 2024-07-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、組合物及其應用
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20250214995A1 (en) 2022-04-28 2025-07-03 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
AU2023300198A1 (en) 2022-06-27 2025-02-13 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1145614C (zh) * 1996-04-12 2004-04-14 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE19908567A1 (de) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911366A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2000051991A1 (en) * 1999-02-27 2000-09-08 Boehringer Ingelheim Pharma Kg 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
NZ516633A (en) * 1999-06-21 2004-09-24 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
CA2403152C (en) * 2000-04-08 2008-10-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Also Published As

Publication number Publication date
NO2014003I1 (no) 2014-06-02
EE05244B1 (et) 2009-12-15
CZ302721B6 (cs) 2011-09-21
EP1345910B1 (de) 2009-04-29
ME02777B (me) 2011-10-10
NO20032726L (no) 2003-06-16
HU228874B1 (en) 2013-06-28
MXPA03005559A (es) 2004-10-14
ZA200304141B (en) 2004-04-15
RS50860B (sr) 2010-08-31
KR20030071787A (ko) 2003-09-06
CA2432428C (en) 2009-09-01
HUS1400005I1 (hu) 2017-08-28
NO325672B1 (no) 2008-07-07
HRP20030504B1 (en) 2011-09-30
EE200300300A (et) 2003-10-15
HRP20030504A2 (en) 2005-06-30
EP2112140A1 (de) 2009-10-28
BRPI0116266B8 (pt) 2021-07-27
ES2326617T9 (es) 2014-09-10
EA006317B1 (ru) 2005-10-27
CA2432428A1 (en) 2002-06-27
DK1345910T3 (da) 2009-07-20
BRPI0116266B1 (pt) 2017-10-31
ES2326617T3 (es) 2009-10-16
CN1277822C (zh) 2006-10-04
CY1109290T1 (el) 2014-07-02
KR100852102B1 (ko) 2008-08-13
PT1345910E (pt) 2009-07-14
WO2002050043A1 (de) 2002-06-27
NZ526918A (en) 2006-11-30
AU1917402A (en) 2002-07-01
JP3827641B2 (ja) 2006-09-27
EP1345910A1 (de) 2003-09-24
AU2002219174B2 (en) 2007-09-06
JP2004516283A (ja) 2004-06-03
DE50114874D1 (de) 2009-06-10
EA200300671A1 (ru) 2004-06-24
BG66139B1 (bg) 2011-07-29
BE2014C009I2 (show.php) 2021-02-04
TWI295992B (en) 2008-04-21
NO2014003I2 (no) 2015-10-19
CY2014008I2 (el) 2015-12-09
BR0116266A (pt) 2004-02-17
IL156277A (en) 2009-12-24
CY2014008I1 (el) 2014-07-02
UA74614C2 (en) 2006-01-16
PL214798B1 (pl) 2013-09-30
PL361798A1 (en) 2004-10-04
BG107929A (bg) 2005-01-31
ATE430136T1 (de) 2009-05-15
IL156277A0 (en) 2004-01-04
CN1481370A (zh) 2004-03-10
LTPA2014005I1 (lt) 2022-05-25
UY27078A1 (es) 2002-07-31
AR040524A1 (es) 2005-04-13
LTC1345910I2 (lt) 2022-06-10
CZ20031930A3 (cs) 2003-10-15
SK7712003A3 (en) 2003-10-07
SI1345910T1 (sl) 2009-08-31
DE10063435A1 (de) 2002-07-04
NO2022028I1 (no) 2022-07-01
NO20032726D0 (no) 2003-06-16
EP1345910B9 (de) 2014-06-04
FR14C0009I1 (fr) 2014-03-07
HUP0301852A2 (hu) 2003-09-29
SK287573B6 (sk) 2011-03-04
MY136086A (en) 2008-08-29
LU92370I9 (show.php) 2019-01-17
HK1060571A1 (en) 2004-08-13
FR14C0009I2 (fr) 2014-11-14
YU49603A (sh) 2006-05-25
HUP0301852A3 (en) 2008-03-28
MEP59508A (en) 2011-05-10

Similar Documents

Publication Publication Date Title
LU92370I2 (fr) Afatinib, les tautomères, les stéréoisomères et les sels de celui-ci, des sels physiologiquement acceptables de celui-ci avec des acides ou bases organiques ou inorganiques, de préférence un sel maléate de celui-ci, et plus de préférence un sel dimaléate de celui-ci
LU92890I2 (fr) Panobinstat ou un sel pharmaceutiquement acceptable, ou un dérivé de celui-ci (farydak)
LU91172I2 (fr) Melagatran, les stéréoisomères de celui-ci, et lessels physiologiquement acceptables de celui-ci (m elagatran astrazeneca).
LU92681I2 (fr) Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate
USD437898S1 (en) Dog
EP1173484A4 (en) TREATMENT OF FIBROSIS BY ANTAGONISM BETWEEN IL-13 AND IL-13 RECEPTOR CHAINS
LU92678I2 (fr) Tobramycine ou un sel pharmaceutiquement acceptable qui en dérive
DE60042351D1 (de) Modulares Kopfsystem zum Ersetzen des proximalen Radiuskopfes.
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
IS2259B (is) Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 undireiningunni
BRAND et al. 200
ITMI20001848A0 (it) Faramaci per l'incontinenza.
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
ITBO990671A0 (it) Maniglione antipanico.
BR0111144B1 (pt) formulaÇço agroquÍmica concentrada em suspensço, e, mÉtodos de preparaÇço de uma mistura de pulverizaÇço e de tratamento de plantas.
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
HU0000307D0 (en) Neuropeptide y antagonists
ITTO20011197A0 (it) Corpo cilindrico ornamentale.
FR2845916B1 (fr) Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
PT1556380E (pt) Derivados de piridoindolona substituidos na posicao 3 por um grupo heterociclico, a sua preparacao e a sua aplicacao em terapeutica.
DZ3480A1 (fr) Sels de sodium de 5-'4-'2-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidine-2,4-dione
WO2001068149A3 (de) Verfahren und verwendung zur biologischen kennzeichnung von tieren, tierprodukten und tierischen erzeugnissen
IT1319459B1 (it) Affondatore per pesca a traina, a posizioni invertite, riaffioranteall'afferrata.
Maksymiuk Experience of Saur Neptun Gdansk
AR038208A1 (es) Composicion farmaceutica dispersable oralmente de mitiglinida